Emerging evidence suggests that the phytocannabinoid CBD may have therapeutic potential for the treatment of agitation in Alzheimer's disease (AD).
Besides modulating the endocannabinoid system, CBD interacts with multiple targets including serotonin, adenosine, dopamine and opioid receptors to exert a broad spectrum of potentially beneficial effects.
This trial's overall objective is to obtain Class 1 evidence regarding the safety and efficacy of CBD (a botanical cannabinoid drug) for managing agitation in patients with AD and to identify novel biomarkers of agitation severity and treatment response. Study will establish whether CBD is beneficial for other relevant outcomes in participants with AD and agitation in comparison to placebo through overall psychiatric symptoms, caregiver distress, cognition, nutritional status, pain, and global function in participants with moderate-to-severe AD over 8 weeks.
Key Details
Study Sponsor: Sunnybrook Research Institute, Centre for Clinical Trail Support (CCTS), and Weston Brain Institute (WBI)
Location: 700 Gordon Street, Whitby, ON (In-person only)
How Often: Every day
Compensation: Yes - for travel purposes
Contact: Dr. Amer Burhan, Geriatric Psychiatrist
905-430-4055